Locatop 0.1%
Locatop 0.1% Uses, Dosage, Side Effects, Food Interaction and all others data.
Locatop 0.1% is a synthetic corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits release of arachidonic acid, hence depresses the formation, release, and activity of chemical inflammatory mediators.
Locatop 0.1% is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Trade Name | Locatop 0.1% |
Generic | Desonide |
Desonide Other Names | Desfluorotriamcinolone acetonide, Desonida, Desonide, Desonidum |
Type | |
Formula | C24H32O6 |
Weight | Average: 416.5073 Monoisotopic: 416.219888756 |
Groups | Approved, Investigational |
Therapeutic Class | Other Topical corticosteroids |
Manufacturer | |
Available Country | France, Lebanon |
Last Updated: | September 19, 2023 at 7:00 am |
![Locatop 0.1% Locatop 0.1%](https://www.medicinesfaq.com/media/png/locatop-0-1.png)
Uses
Locatop 0.1% gel is used for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
Locatop 0.1% is also used to associated treatment for these conditions: Dermatosis, Ocular Inflammation, Mild Atopic dermatitis, Moderate Atopic dermatitis
How Locatop 0.1% works
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Dosage
Locatop 0.1% dosage
Topical/Cutaneous-Corticosteroid-responsive dermatoses:
- Adult: As 0.05% cream, oint, or lotion: Apply sparingly onto the affected areas 2-4 times daily until optimal response is achieved. Max duration of therapy: 8 wk.
- Child: ≥ 2 yr Same as adult dose.
Atopic dermatitis:
- Adult: As 0.05% foam or gel: Apply to affected area(s) bid. Max duration of therapy: 4 wk.
- Child: ≥3 mth Same as adult dose.
Side Effects
The most common local side effects are burning, rash and pruritus at application site. The following additional local side effects have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Precaution
Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression thru ACTH stimulation test, plasma cortisol test and urinary free cortisol test; signs and symptoms of bacterial or fungal infection.
Interaction
Enhanced effect with other topical corticosteroids.
Food Interaction
No interactions found.Elimination Route
Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Pregnancy & Breastfeeding use
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Therefore, Locatop 0.1% gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Caution should be exercised when Locatop 0.1% gel is administered to a nursing woman.
Contraindication
Locatop 0.1% gel is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Special Warning
Pediatric use: Safety and effectiveness of Locatop 0.1% gel in pediatric patients less than 3 months of age have not been evaluated, and therefore its use in this age group is not recommended.
Acute Overdose
Topically applied Locatop 0.1% gel can be absorbed in sufficient amounts to produce systemic effects.
Storage Condition
Store in a cool & dry place. Protect from light.
Innovators Monograph
You find simplified version here Locatop 0.1%
Locatop 0.1% contains Desonide see full prescribing information from innovator Locatop 0.1% Monograph, Locatop 0.1% MSDS, Locatop 0.1% FDA label